Massivemarkets

ABUS

Arbutus Biopharma Corporation Common Stock

Nasdaq · usd

$3.88+0.00 (+0.02%)
As of 12:40:14 PM EST on Nov 12, 2026 · 15-minute delayed

Arbutus Biopharma Corporation Common Stock (ABUS) trades at $3.88 (+0.02%) as of 12:40:14 PM EST on Nov 12, 2026, -7.40% over the past month. Market cap is $594.78M, with 9.1 days to cover in short interest.

Stock performance

How Arbutus Biopharma Corporation Common Stock (ABUS) stock has performed from one day to one year, with its 52-week range.

+0.91%
+$0.03 over 1D
$3.82$3.85$3.88$3.914:25 AM10:10 AM11:00 AM11:50 AM12:40 PM$3.89
1D
+0.00%
1W
+5.72%
1M
-7.40%
YTD
-19.33%
1Y
-14.91%
52-wk range
$3.50 – $5.45

Key statistics

Today's trading snapshot for ABUS: day range, open, previous close, volume and market cap.

Day range
$3.81 – $3.92
Open
$3.86
Prev close
$3.88
Volume
860.48K
Market cap
$594.78M
Shares out
198.11M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Arbutus Biopharma Corporation Common Stock: P/E, P/S, P/B, ROE and more.

P/E
3.83
P/S
3.22
P/B
2.26
P/FCF
—
ROE
59.1%
ROA
55.8%
Debt/Equity
0.01
Div yield
0.00%

As of Nov 10, 2026

8-K filings

Material corporate events Arbutus Biopharma Corporation Common Stock has disclosed to the SEC on Form 8-K.

  • Quarterly earningsNov 10, 2026

    On November 10, 2026, Arbutus Biopharma Corporation ("Arbutus") issued a press release announcing its financial results for the third quarter ended September 30, 2026 and certain other information.

  • On October 22, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company's oral PD-L1 inhibitor.

  • Tender offerAug 21, 2026

    On August 21, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its plans to launch a modified "Dutch auction" tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.

  • Deal terminationJul 16, 2026

    On July 15, 2026, Arbutus and Genevant entered into a termination agreement (the 'Termination Agreement') filed herewith as Exhibit 10.1 to terminate the RSV Agreement. Pursuant to the Termination Agreement, Genevant will pay Arbutus a termination fee of $1.0 million within ten business days of the date of the Termination Agreement, and all rights or obligations under the RSV Agreement are terminated.

  • Annual meeting resultsMay 27, 2026

    On May 26, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company's shareholders voted and: (1) elected each of the Company's nominees for director; (2) approved the adoption of the 2026 Plan, (3) approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular; and (4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

ABUS short interest

How heavily ABUS is shorted: shares short, days to cover and average daily volume.

Days to cover
9.1
Short interest
19.89M
Avg volume
2.18M

As of · reported to FINRA twice monthly.

ABUS news

The latest news and headlines about Arbutus Biopharma Corporation Common Stock (ABUS).

Frequently asked questions

What is the Arbutus Biopharma Corporation Common Stock (ABUS) stock price today?

Arbutus Biopharma Corporation Common Stock (ABUS) is trading at $3.88 (+0.02% on the day) as of 12:40:14 PM EST on Nov 12, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Arbutus Biopharma Corporation Common Stock?

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a…

What is the short interest in ABUS?

As of Oct 30, 2026, ABUS has 19.89M shares short and 9.1 days to cover.

What exchange is ABUS listed on?

Arbutus Biopharma Corporation Common Stock (ABUS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of ABUS with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ABUS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.